nanotech-investing Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer
nanotech-investing Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer
nanotech-investing Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen
nanotech-investing Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025
nanotech-investing Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors
nanotech-investing Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules
nanotech-investing Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules
nanotech-investing Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing
Tartisan Nickel Corp. Appoints Jack Jacobs, Congressional Medal of Honour Recipient, Retired Army Colonel and Distinguished Business Executive to Board of Advisors
